Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials. - Wikidata - wikimedia - TriplyDB

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials.

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials.

http://www.wikidata.org/entity/Q37639881

about

Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.

P2860

Q41059063-C703CA64-696B-4479-9B92-023172757448 Q41217657-D8D2143F-8859-4508-A8C1-EAF2DA819747

P2860

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials.

http://www.wikidata.org/entity/Q37639881

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Etravirine as a Switching Opti ...... on: A Review of Recent Trials.

@en

Etravirine as a Switching Opti ...... on: A Review of Recent Trials.

@nl

type

label

Etravirine as a Switching Opti ...... on: A Review of Recent Trials.

@en

Etravirine as a Switching Opti ...... on: A Review of Recent Trials.

@nl

prefLabel

Etravirine as a Switching Opti ...... on: A Review of Recent Trials.

@en

Etravirine as a Switching Opti ...... on: A Review of Recent Trials.

@nl

P1433

Q37639881-3033A7B1-2699-4A9E-886E-A930E18C153C

P1476

Q37639881-6EA50F37-B6E9-4FA5-BEFB-6C33C021169F

P2093

Q37639881-72C7265A-3468-4589-9BB5-11028984AD1C

Q37639881-95172D7D-50A8-4B51-B357-EB45D2FF5D15

Q37639881-EF0F6535-FBBD-4698-835E-8430781DF28E

P2860

Q37639881-02F30BC5-AB29-4CE9-AE06-2FDFFF196877

Q37639881-0C3478F2-C473-49D5-9102-9B2A3094E5CB

Q37639881-0E48BBC0-F4D5-4181-81CF-CBF2B0058952

Q37639881-0E9B22D2-DE4D-415A-945F-05B5290AE5CD

Q37639881-1B787293-2139-4734-9F9F-CA3887BADFB2

Q37639881-2643F7F9-3B8B-4B83-9ADE-0FD56E1A7F22

Q37639881-47FB3AD6-D178-4F0F-AD3F-0406C7A474FF

Q37639881-5B154243-7D22-4169-B4C0-2F458D93F377

Q37639881-5D5C4414-9579-47A0-A447-39B7EBA96F71

Q37639881-5E3B0641-18ED-4B21-A8C4-78045A02E633

P304

Q37639881-899467D2-2FB9-4A74-87FC-B22E739AB681

P31

Q37639881-8CC3C783-4246-4E28-A894-C929C4786A40

P356

Q37639881-F37234D6-40AB-4C04-BE31-7CACC7A51953

P478

Q37639881-DDC36DC5-E605-4DE4-AECC-6AE3D46E7844

P50

Q37639881-20FC5122-BF35-4A99-85A3-2BEC83D32B40

P577

Q37639881-BF611BB3-6DF2-4DA5-A058-BD4FF1A00E3C

P5875

Q37639881-16A7502D-2594-4535-9B2D-A26AF6B8947A

P698

Q37639881-E4760D48-2BEA-435D-992D-57A86E62AFD3

P932

Q37639881-D9328B54-1A37-47CA-B92F-092BC32CBAE3

P356

P1433

AIDS Research and Treatment

P1476

Etravirine as a Switching Opti ...... ion: A Review of Recent Trials

@en

P2093

Andrew Hill

http://www.w3.org/2001/XMLSchema#string

Christiane Moecklinghoff

http://www.w3.org/2001/XMLSchema#string

Mark Nelson

http://www.w3.org/2001/XMLSchema#string

P2860

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.

Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Designing and interpreting HIV noninferiority trials in naive and experienced patients.

Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.

Class-sparing regimens for initial treatment of HIV-1 infection.

Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.

Clinical pharmacokinetics and pharmacodynamics of etravirine.

P304

636584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/636584

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261517782

http://www.w3.org/2001/XMLSchema#string

P698

24715982

http://www.w3.org/2001/XMLSchema#string

P932

3955667

http://www.w3.org/2001/XMLSchema#string